UPC Analytics
DEEN
Übersicht · Eingereicht: —

UPC_APP_16366/2025

RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME

Prozessuale & UnteranträgeRücknahmeanträgeMilan CDApplication Rop 265—Vergleich erfolgt: Vor Hauptsache
ÜbersichtEntscheidungenDokumenteZeitverlauf
Parteien

Kläger

  • Pfizer, Inc.
  • Pfizer Europe MA EEIG
  • Pfizer B.V.
  • Pfizer S.A.
  • Pfizer Manufacturing Belgium S.A.
  • Pfizer Service Company S.R.L.
  • Pfizer Pharma GmbH
  • Pfizer Limited
  • Pfizer Corporation Austria GmbH
  • Pfizer Aps
  • Pfizer Oy
  • Pfizer SAS
  • Pfizer S.r.l.
  • Laboratórios Pfizer, Lda.
  • Pfizer AB
  • Pfizer Luxembourg S.a.r.l.
Vertreter: Gareth Williams

Beklagte

  • GlaxoSmithKline Biologicals SA
Vertreter: Oliver Jan Juengst; Daniela Kinkeldey
Richter
  • Andrea PostiglionePresiding Judge
  • Anna-Lena KleinJudge-Rapporteur
  • Steen Lyders Wadskov-HansenTechnically Qualified Judge
Patente
  • EP 4183412
CPC-Codes: C12N2760/18522, C12N2760/18534, A61K2039/55505, A61K2039/5258, A61K2039/55566, A61K39/155, A61K39/12, C07K2319/73, A61K2039/53, C07K2317/76, A61P31/14, A61P37/04…

Sektor: Biotechnology

Ausgang
Zurückgenommen
Eingereicht: —
Erste Entscheidung: 22. Apr. 2025
Sprache: —
Vergleich erfolgt: Vor Hauptsache

Milan Central Division procedural order granting Pfizer's application to withdraw a revocation action against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV F protein vaccine patent), and a separately filed counterclaim for revocation in parallel Düsseldorf infringement proceedings (which had been referred to the Central Division). Pfizer and Glaxo had each filed applications to amend the patent; both revocation actions were withdrawn by Pfizer prior to closure of the written procedure. The court also ordered 60% reimbursement of court fees and confirmed each party bears its own costs.